



- *Vice Chair of Research, Medicine Office of Research*
- *Professor*
- *Department of Medicine*

Conditions Treated:

Research Areas:

- *Chronic Beryllium Disease*
- *Cystic Fibrosis (CF)*
- *Cancer*
- *Infectious Diseases*
- *Basic Immunology*
- *Environmental and Occupational Diseases*
- *Inflammation*
- *Oxidative Stress*

Research Interests

Cystic Fibrosis, COPD, chronic beryllium disease, interstitial lung disease, sulfur mustard lung injury, drug development. Adaptive glutathione responses to cigarette smoke in COPD. (NIH RO1 HL084469-05) (Primary Investigator). Novel Antioxidant Therapeutics for Sulfur Mustard Toxicity. (NIH U54 ES015678-06) (Project 2 Leader). Modulation of lung inflammation by CFTR-dependent thiols. (Cystic Fibrosis Foundation Research Grant) (Primary Investigator). Targeting oxidative stress in chronic beryllium disease. (NIH RO1 ES017582-04) (Multiple Primary Investigator).

Education

1984 University of Montana (Missoula, MT), BS with Honors, School of Pharmacy
1992 Purdue University (W Lafayette, IN), PhD, Pharmacology and Toxicology

Fellowship

1995 Duke University (Durham, NC), Post-doctoral Integrated Toxicology & Pulmonary Fellow

Affiliations with the University of Colorado Denver

Professor of Medicine, Pharmaceutical Sciences and Immunology, University of Colorado Denver
Professor, Colorado School of Public Health, University of Colorado Denver

Professional Memberships

Society of Toxicology
American Thoracic Society
Society of Free Radical Biology and Medicine
American Heart Association
American Chemical Society

Awards & Recognition

Basic Sciences Section Head, Department of Medicine, National Jewish Health
Chief Science Officer, Aeolus Pharmaceuticals
Chairman, Board of Publications Committee, Mechanisms Specialty Section Councilor, Society of Toxicology
NIH Study Section Member, LIRR

Publications

Dobis, D.R., Sawyer R.T., Gillespie M.M., Huang J., Newman L.S., Maier L.A. and Day B.J. Modulation of Lymphocyte Proliferation by Antioxidants in Chronic Beryllium Disease. *Am. J. Respir. Crit. Care Med.* 177:1002-1011, 2008.

Day, B.J. Antioxidants as potential therapeutics for lung fibrosis. *Antiox Redox Sig*,10:355-370, 2008.

Kachadourian, R and Day, B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. *Free Radic. Biol. Med.* 41:65-76, 2006.

Velsor, L.W., Kariya C.,Kachadourian, R., and Day, B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. *Am. J. Respir. Cell Mol. Biol.* 35:579-586, 2006.

Day BJ, van Heeckeren AM, Min E, and Velsor L. Role for CFTR in a glutathione response to bronchopulmonary pseudomonas infection. *Infect Immun* 72:2045-2051, 2004.

Doctor's Contact Information

Office: 877.225.5654

Locations

National Jewish Health Main Campus
1400 Jackson St.

Denver, CO 80206